- About Allist
- R & D
On August 3, the 14th China Health Forum released the "List of Top 10 New Drugs (in China)", which has attracted great attention from the industry, and furmonertinib mesylate (brand name: Ivesa®) was awarded the honor.
Pursuing the mission of "advancing long life with innovation of science and technology", Allist is committed to developing and producing safe, effective, and inclusive innovative drugs with independent intellectual property rights. The company seeks to develop China's own anti-cancer medicines through independent innovation.
Ivesa® is a Class 1 new drug developed by Allist through eight years of independent R&D, with independent intellectual property rights. As a high quality, effective and affordable Chinese original innovative drug, Ivesa® will promote the holistic development of health China and contribute to the well-being of patients in China and even around the world, through excellent efficacy in clinical practices!
China Health Forum
China Health Forum is co-organized by People's Daily Health Client Platform and Health Times of People's Daily. It is one of the earliest, most influential, highest-quality and most authoritative conferences in China's healthcare industry regarding the theme of “Healthy China". It has been held for fourteen years and is a national high-end forum involving the participation of the Party and government at all levels, pharmaceutical and health management institutions, medical, pharmaceutical, healthcare and media communities.
Based on dimensions covering annual innovation, clinical breakthrough, drug benefits and public attention, the list of top ten new drugs (in China) released by the 14th China Health Forum targets a number of major or highly prevalent diseases and fills in the gap of multiple treatment areas. These were developed under independent research and development, and are first-in-class drugs in China or even worldwide.
The selection work for the list of the 14th China Health Forum was kicked off on October 7, 2021, and lasted for 7 months. The list advisory committee, academic committee, working group and other related working bodies were established to develop the inclusion criteria for each list. The list working group solicited extensive opinions by means of industry experts' recommendation, industry interviews and data verification, and followed the evaluation criteria to create the candidate list. The results of the list were finally determined by the deliberation of academic committee and public voting on the Internet.
The innovative introduction of a trifluoroethoxypyridine structure in furmonertinib makes it "potent against brain metastases, with excellent efficacy, safety and wide therapeutic window".
In March 2021, furmonertinib was approved for the treatment of adult patients with locally advanced or metastatic NSCLC who experienced disease progression during or after prior treatment with EGFR tyrosine kinase inhibitors (TKI) and who were tested positive for the EGFR T790M mutation. After 9 months, Ivesa® was included in the National Reimbursement Drug List for use in the second-line treatment for NSCLC.
In June 2022, Ivesa® was approved for use in the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.
The FURLONG study was published in full text in The Lancet Respiratory Medicine online in June 2022. In FURLONG study, a phase III clinical study on EGFR TKI monotherapy for the first-line treatment of patients with advanced NSCLC with EGFR-sensitive mutations, furmonertinib is the first third-generation EGFR TKI that has achieved a primary endpoint PFS of more than 20 months and a 56% reduction in the risk of disease progression or death.